StockData
Lakewood-Amedex Biotherapeutics Inc. logo

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock

LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.21−0.00 (-2.23%)

Close on Nov 17, 2026Market cap $508.30KP/E –Yield –

Lakewood-Amedex Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$733.10K+399.0%
Q2 FY2026Jun 30, 2026$503.02K+196.4%
Q1 FY2026Mar 31, 2026$182.15K–
Q3 FY2025Sep 30, 2025$752.93K–
Q2 FY2025Jun 30, 2025$146.90K–
Q1 FY2025Mar 31, 2025$169.70K–

More Lakewood-Amedex Biotherapeutics figures

See a number that looks wrong?